Cancer Carepartners: Improving patients' symptom management by engaging informal caregivers by Silveira, Maria J et al.
STUDY PROTOCOL Open Access
Cancer Carepartners: Improving patients’
symptom management by engaging informal
caregivers
Maria J Silveira
1,2*, Charles W Given
3, Kemp B Cease
2,4, Alla Sikorskii
5, Barbara Given
3, Laurel L Northouse
6 and
John D Piette
1,2
Abstract
Background: Previous studies have found that cancer patients undergoing chemotherapy can effectively manage
their own symptoms when given tailored advice. This approach, however, may challenge patients with poor
performance status and/or emotional distress. Our goal is to test an automated intervention that engages a friend
or family member to support a patient through chemotherapy.
Methods/Design: We describe the design and rationale of a randomized, controlled trial to assess the efficacy of
10 weeks of web-based caregiver alerts and tailored advice for helping a patient manage symptoms related to
chemotherapy. The study aims to test the primary hypothesis that patients whose caregivers receive alerts and
tailored advice will report less frequent and less severe symptoms at 10 and 14 weeks when compared to patients
in the control arm; similarly, they will report better physical function, fewer outpatient visits and hospitalizations
related to symptoms, and greater adherence to chemotherapy. 300 patients with solid tumors undergoing
chemotherapy at two Veteran Administration oncology clinics reporting any symptom at a severity of ≥4 and a
willing informal caregiver will be assigned to either 10 weeks of automated telephonic symptom assessment
(ATSA) alone, or 10 weeks of ATSA plus web-based notification of symptom severity and problem solving advice to
their chosen caregiver. Patients and caregivers will be surveyed at intake, 10 weeks and 14 weeks. Both groups will
receive standard oncology, hospice, and palliative care.
Discussion: Patients undergoing chemotherapy experience many symptoms that they may be able to manage
with the support of an activated caregiver. This intervention uses readily available technology to improve patient
caregiver communication about symptoms and caregiver knowledge of symptom management. If successful, it
could substantially improve the quality of life of veterans and their families during the stresses of chemotherapy
without substantially increasing the cost of care.
Trial Registration: NCT00983892
Background
Cancer is a prevalent problem that causes much suffering
among patients and families. Most interventions to
improve symptom control require patients to engage in
activities such as managing medications, altering diets, or
accessing outside resources that may be beyond their reach
due to limitations in physical and mental functioning.
Social network members inside and outside of the patient’s
household can assist with symptom monitoring, medica-
tion adherence, managing clinical encounters, and coping
emotionally. Hogan et al found that among 92 studies
meeting their entry criteria, 73 reported some benefit of
social support provided by friends and families to patients
with chronic conditions [1]. Unfortunately, cancer care-
givers often lack the skills and resources they need to help
the patient manage their treatment and the negative conse-
quences of their disease and its management. * Correspondence: mariajs@umich.edu
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designed to engage both patients and caregivers [2-11].
Among programs that have been evaluated, the majority
of studies have had serious methodological flaws or lim-
ited evidence of effectiveness [8,12]. Northouse and collea-
gues examined the effects of three nurse home visits and
two follow up nurse calls over four months to patients
with prostate cancer and their spousal caregivers, with the
goal of improving caregiver involvement, attitudes, coping,
and quality of life [13]. Results showed some improve-
ments in patient outcomes (better spousal communication
and less uncertainty) and multiple improvement in care-
giver outcomes (higher quality of life, self-efficacy, and
communication; less symptom distress and negative
appraisal of caregiving), with some effects sustained to 12
months follow-up. Given and colleagues tested the effects
of a cognitive behavioral intervention administered by a
nurse via telephone to assist patients undergoing che-
motherapy to manage symptoms and assist caregivers to
become involved in supporting symptom management.
Patients receiving the intervention reported 34% and 30%
lower symptom severity at 10 and 20 weeks, respectively
[11]. Caregivers did not report any change in their involve-
ment or distress, and some caregivers reported increased
depressive symptoms [14,15].
The current protocol describes an ongoing randomized
trial designed to address these gaps in the literature by
developing and evaluating an intervention that provides
cancer patients and caregivers with the information they
need to make effective management decisions, decrease
symptom burden, and improve patient and caregiver out-
comes. The study was funded by the VA Health Services
Research and Development Service and began October,
2009. The trial will be completed in August 2013.
The intervention uses a Web-enabled program to alert
caregivers of patients’ symptoms and provide them with a
framework for identifying problems, receiving structured
advice, and following up to assist the patient in manage
symptoms while receiving chemotherapy. Specifically, the
intervention includes weekly, automated telephonic symp-
tom assessment with self-management support calls to
patients paired with Web-based caregiver alerts that
include customized advice. The study will enroll 300
patients with solid tumors undergoing chemotherapy iden-
tified from two Department of Veterans Affairs (VA) out-
patient oncology clinics. Patients are recruited along with
an informal caregiver willing to play a limited role in
assisting the patient with symptom management. The
impact of the intervention will be evaluated relative to a
control arm in which patients receive automated telepho-
nic symptom assessments and self-management advice
without any involvement of their identified caregiver.
Thus this is one of the few rigorously designed interven-
tions that tests the value added impact of engaging
informal caregivers in symptom management for patients
with cancer. Specific study hypotheses are as follows:
Hypothesis 1a: Patients receiving automated telephonic
symptom assessment and management advice, with Web-
based feedback to inform and engage a caregiver, will
report less frequent and less severe symptoms at 10 and 14
weeks when compared to patients receiving automated tele-
phonic symptom assessment and management advice
alone. Intervention-group patients will also report better
physical function, fewer outpatient visits and hospitaliza-
tions related to symptoms, and greater adherence to
chemotherapy.
Hypothesis 1b. The effect of the intervention on symptom
severity, physical functioning, and utilization of services
will be partially mediated by improved patient self-efficacy
and actualized social support.
Hypothesis 2a: Caregivers receiving the intervention
will provide significantly more social support to patients
at 10 and 14 weeks as evidenced by increases in patient-
reported measures of social support when compared with
caregivers who do not receive the intervention.
Hypothesis 2b: Caregivers receiving the intervention
will report lower perceived caregiving burden and dis-
tress compared to caregivers in the comparison group.
Theoretical Model
The study is based on the stress-coping model which iden-
tifies the processes influencing quality of life in patients
with cancer (Figure 1) [16,17]. According to this model,
when a cancer patient develops a need-e.g. a symptom-s/
he is able to address the need to the extent that s/he is
self-efficacious and functional. The system we are evaluat-
ing improves patient self-efficacy by providing patients
with tailored information about what they can do to feel
better. By activating an informal caregiver to support the
patient, there is an additional source of information and
encouragement to promote the patient’ss e l f - e f f i c a c y .H o w
the patient uses the information provided during auto-
mated telephonic interactions determines his/her quality
of life, ability to comply with chemotherapy, and utiliza-
tion of services. The proposed intervention serves not only
to improve patient access to information, but also to
increase the speed of information transfer between patient
and caregiver.
Intervention Components
Automated Telephonic Symptom Assessment (ATSA)
ATSA is an automated telephonic system that calls
patients at home to collect their symptom ratings via
responses to recorded queries using their telephone’s
touchtone keypad. ATSA’sq u e s t i o n sc o n s i s to fi t e m s
from the MD Anderson Symptom Inventory modified
for the telephone and validated in prior cognitive-beha-
vioral studies of symptom management [15,18-21]. The
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showing that patients with cancer and other serious
chronic diseases can and will report reliable information
during automated assessment calls, and that such calls
may improve their self-care and health outcomes
[22-25]. The duration and intensity of the intervention
is premised on past work that suggesting that ATSA’s
benefits peak at 10 weeks [26].
The ATSA system calls patients weekly and asks them
to rate the frequency and severity of eight core symptoms:
pain, distress, fatigue, insomnia, nausea, poor appetite, dry
mouth, and constipation. The choice of core symptoms is
based on prior work by Given and colleagues showing that
among patients undergoing chemotherapy, 85% experi-
ence at least one of these symptoms [11]. Patients are
asked how many days during the last week they have
experienced each symptom. When patients report a fre-
quency of once per week or greater, the ATSA prompts
patients to rate the severity of that symptom on a scale of
0t o 1 0 .
During the automated telephonic interaction, the
ATSA system gives targeted advice for self-management
depending upon the severity of the symptoms reported
by the patient. For a severity of three or less, ATSA gives
no advice. For a severity greater than three, ATSA refers
the patient to the appropriate section of a printed “Symp-
tom Management Toolkit” which the patient receives
upon study enrollment. Details about the Toolkit are
provided below. When a symptom is reported with a
severity of seven or higher, ATSA not only refers the
patient to the appropriate section of the Toolkit, but also
recommends that the patient contact his/her VA oncol-
o g yp r o v i d e r .T h ec u tp o i n t so f3a n d7w e r ec h o s e n
based on severity scores shown to have similar levels of
interference with functioning among patients with cancer
[21]. If an ATSA call is not completed at the designated
time, the system automatically attempts a repeat call
twice at 15 minute intervals. If not completed that day,
another call is attempted on the next day at the same
time. ATSA stores data on patients’ symptom scores as
well as the number of attempted call assessments, date/
time stamps for all call attempts, and the number of
missed call attempts for the purposes of evaluating ser-
vice usability.
The Symptom Management Toolkit
The Toolkit is a printed, patient guide for managing
symptoms commonly seen in cancer, organized by symp-
tom in a question/answer format. The Toolkit was devel-
oped by Charles W Given and Barbara Given for use in
A T S A .S t r a t e g i e si n c l u d e di nt h eT o o l k i ta r eb a s e do n
recommendations from the National Comprehensive
Cancer Network, National Institutes of Health, Oncology
Nursing Society, and other groups of nationally recog-
nized experts, supplemented by literature gained from
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Figure 1 Depiction of theoretical model. CG = caregiver; CR = care recipient.
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PubMed for evidence-based interventions [27-29]. The
Toolkit has been successfully used by both patients and
in-home caregivers to manage symptoms in patients
undergoing chemotherapy in five prior studies
[11,14,15,20,30].
Cancer CarePartners
Cancer CarePartners is a Web based resource that draws
information from the ATSA calls and uses that as well as
a detailed set of caregiver support tools to provide care-
givers with assistance in decision-making and instrumental
assistance to improve patients’ symptom management.
Following each of patients’ ATSA assessments, Cancer
CarePartners alerts the caregiver about the patient’s symp-
toms and helps the caregiver develop strategies for addres-
sing the patient’s needs. Cancer CarePartners was
designed based on the problem-solving conceptual frame-
work established by D’Zurilla and Nezu for family care-
givers of people with physical illnesses [31]. In this
framework, problem solving is seen as the rational and
systematic construction of a solution through the use of
four specific problem solving skills: 1) problem definition
and formulation, 2) generation of alternatives, 3) decision
making, and 4) solution implementation and verification.
Table 1 summarizes how Cancer CarePartners develops
these four skills in cancer caregivers; screenshots are
shown in Figure 2.
Methods
The intervention’s efficacy is being evaluated using a
randomized, controlled trial among patients undergoing
a course of chemotherapy at two Department of Veter-
ans Affairs (VA) oncology clinics located in Ann Arbor,
MI and Fargo, ND. Three hundred patients with solid
tumors undergoing chemotherapy and reporting at least
one core symptom at a moderate level are being
assigned to either 10 weeks of weekly ATSA contacts or
10 weeks of weekly ATSA contacts plus caregiver alerts
and access to the Cancer CarePartners website. The
duration and intensity of the intervention is premised
on past work suggesting that ATSA’s benefits peak at 10
weeks [11].
T h eg o a lo ft h es t u d yi st od e t e r m i n ei f ,w h e nc o m -
pared to a comparison group receiving ATSA alone,
patients who receive ATSA and whose caregivers receive
access to Cancer CarePartners will report: significantly
less total symptom severity; and secondarily improved
physical functioning, adherence to chemotherapy, and
more appropriate utilization of health services at 10
weeks. The study also will determine whether caregivers
provide more social support and report less caregiver
burden and distress.
Patients and caregivers will be surveyed at intake, 10,
and 14 weeks. Further, we will track patient participa-
tion with ATSA and (in the experimental arm) caregiver
use of the Website and social support provided, allowing
for indicators of intervention dose to be incorporated
into our analyses. Finally, all patients will receive routine
oncology, hospice, and/or palliative care.
Eligibility
Study patients must be 21 years or older, cognitively
intact, English speaking, able to hear, and able to use
t h ep h o n e .T h e ym u s th a v eh o m ea c c e s st oat o u c h -
tone telephone. They must have a solid tumor; for
example, prostate, lung, colorectal, breast, non-Hodgkin
lymphoma, or head/neck cancer. Patients may have new
or recurrent disease in early or late stage. All patients
Table 1 Cancer CarePartners Web site components and caregiver skills targeted.
Targeted caregiver skills Web site components
Problem definition &
formulation
® Upon logging into the Cancer CarePartners web site, the caregiver sees a depiction of the patient’s last symptom
scores using horizontal thermometers (Figure 1a). Symptoms are presented in order of severity, with the most
severe symptoms displayed at the top of the screen. Caregivers can select a symptom to access additional
information about the symptom’s cause and management (Figure 1b). Caregivers also can access reports
showing trends in each symptom over time.
Generation of alternatives ® The Web site asks caregivers to identify one symptom that they would like to help the patient work on that
week. Upon choosing the symptom, the caregiver sees a list of recommendations suited to the patient’s last
assessment (Figure 1c). Advice is grouped by its targeted domain: namely, activity (i.e. exercise), communication,
diet, medication, and mood. For example, if the patient reported dry mouth and the caregiver chooses to
address that symptom with additional self-care assistance, they may receive advice such as “make sure the
patient has a water bottle at his/her side at all times.”
Decision making ® Caregivers are asked to commit to trying three to five tasks for the week from the list of recommendations. To
help caregivers make informed decisions about which recommendations to adopt, the Web site describes each
task’s purpose and what is involved, and provides examples for how to accomplish it.
Solution implementation &
verification
® After committing to 3-5 tasks, caregivers can print a list of their choices, or “Task List, “ for future reference
(Figure 1d). The next time the caregiver logs into the website, she is asked which of the tasks she attempted and
whether the recommended action was helpful (Figure 1e). In addition to allowing caregivers to self-monitor the
outcomes associated with their assistance, the data allow the investigative team to determine uptake of specific
advice offered by Cancer CarePartners and caregivers’ perceptions about its benefit.
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if they are being treated for recurrent disease, must have
experienced a treatment free interval of 10 weeks
between the new and past treatment. Patients may live
alone or with others, with or without an in-home care-
giver. Patients are excluded if they have been diagnosed
with a hematologic malignancy or their treatment regi-
men involves bone marrow transplantation because such
patients’ symptom profiles differ from those of other
cancer patients. Also, patients will be excluded if they
(a) have untreated mental illness or cognitive impair-
ment limiting their ability to participate with ATSA, (b)
cannot identify at least one potential consenting care-
giver, (c) are institutionalized or enrolled in hospice
prior to enrollment, or (d) plan to discontinue receiving
the majority of care from one of the study sites during
the follow-up period.
For the purposes of this study, a potential caregiver is
defined as a person living inside or outside of the
patient’s household who has at least monthly contact
with the patient, either by phone or in person, and is
willing to help the patient manage his/her symptoms.S /
he must be 21 years or older, cognitively intact, English
speaking, and able to hear and speak English for tele-
phone interviews. S/he must have access to a telephone
and computer with a high-speed Internet connection.
Caregivers need not be providing direct care prior to
the study; indeed, a major motivation for this interven-
tion is that many well-intentioned friends and family
members would be willing to provide more cancer
Figure 2 Screen shots of Cancer CarePartners Web site.
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structure in place to make that possible. Caregivers will
be excluded if they, themselves, are on active treatment
for cancer. They will also be excluded if they have
poorly controlled mental illness, moderate cognitive
impairment, or are unable to be interviewed by
telephone.
Recruitment & Randomization
Study staff review the schedules of participating che-
motherapy infusion clinics weekly to identify potentially
eligible patients. The list of potentially eligible patients
is provided to staff oncologists for their approval prior
to attempting recruitment.
Eligible patients are approached by research assistants
after their second week of chemotherapy. Research staff
explain the study to them, screen for eligibility, offer
enrollment, and obtain informed consent. Patients agree-
ing to participate are asked to identify at least four poten-
tial caregivers using an algorithm based on the Norbeck
Social Support Scale to determine the ranking of choices
according to their involvement in the patient’s life [32,33].
Research assistants then obtain contact information for
the potential caregivers. Potential caregivers are recruited
by research assistants by phone or in person if they
accompany the patient to clinic. The research assistants
explain the study, screen for eligibility, and obtain written
informed consent. When a potential caregiver declines
participation in the study, the research assistants contact
the remaining potential caregivers on the list following the
ranking provided by the patient. If no potential caregiver
consents to participate, the patient is excluded from the
study.
Patient participants are asked to identify preferred call-
ing times for their ATSA calls. In addition, they are
instructed on the use ATSA and rehearse an ATSA
symptom assessment with the research assistant while in
clinic. All patient participants are told to contact the pro-
ject manager if they have any questions during their par-
ticipation in the study anda r eg i v e nt h et e l e p h o n e
number for their respective oncology clinic for clinical
issues not related to the study or when advised to do so
by ATSA.
Basic sociodemographic and clinical data are kept on
patients and caregivers who are ineligible for or refuse
enrollment in order to understand the reach of the
intervention in the broader population of eligible
patients. In particular, we will describe the extent to
which the requirement of caregiver Internet access
serves as a barrier to recruitment among economically
disadvantaged or rural patients.
After completing the baseline assessment, participating
patients are randomized to either the control or inter-
vention arm by a computer minimization program that
balances the arms for type of cancer (lung vs. other) and
the type of caregiver (in-home vs. out of home). The
minimization procedure, known as ‘adaptive randomiza-
tion’ balances trial arms according to the history of pre-
vious allocations. Arms are being balanced for lung
cancer since patients with lung cancer have a symptom
pattern distinct from patients with other solid tumors
[34,35]. Arms are being balanced for type of caregiver
because in-home caregivers have more access to the
patient than do caregivers living at a distance and,
hence, more opportunities for providing support.
Comparison group
Patients randomized to the control arm of the study
receive the Symptom Management Toolkit followed by
weekly ATSA calls for 10 weeks. Caregivers in the con-
trol arm receive an email with a PDF copy of “What
you need to know about cancer” from the National Can-
cer Institute (available from http://www.cancer.gov/can-
certopics/wyntk/colon-and-rectal/page1). This booklet
on cancer discusses possible causes, symptoms, diagno-
sis, treatment, emotional issues, and questions to ask
the doctor.
Intervention group
Patients randomized to the intervention arm receive the
Symptom Management Toolkit and weekly ATSA calls
for 10 weeks, as received by control-group participants.
In addition, however, their caregiver receives weekly
emails prompting them to log into the Cancer CarePart-
ners website when their patient reports any core symp-
tom severity of four or higher. The website informs
caregivers of their patients’ symptom assessment scores
and provides them with advice for how to help, as
described above. For the first 4 weeks in the study, staff
monitor each caregiver’s use of the website. When care-
givers do not log into Cancer CarePartners within 48
hours of an assessment, staff telephone them to trouble-
shoot as needed.
Data Sources
Data are being gathered from patient and caregiver sur-
veys, ATSA, the Cancer CarePartners website, and med-
ical record review.
Patient & caregiver surveys
Research assistants interview patients and caregivers by
phone at baseline, 10 weeks post baseline, and 14 weeks
post baseline. Patient surveys assess the study primary
outcome (i.e. symptom severity) and secondary out-
comes (i.e. physical and mental functioning, adherence
to chemotherapy, and utilization of health services). Sur-
veys also gather data on potential mediators of interven-
tion effects (i.e. self-efficacy and actualized social
support). Goals of the caregiver surveys are to measure
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and caregivers receive $15 for each completed survey.
ATSA
ATSA tracks call attempts, call outcomes (completed vs.
incomplete), and reported symptom scores. The number
of completed calls relative to call attempts will be used
to describe patient uptake of the intervention as well as
the dose received.
Cancer CarePartners website
The website tracks the number of email alerts sent to
caregivers, numbers of log-in attempts, the web pages
visited, the time spent per page, the tasks chosen, and
caregivers’ responses to the weekly task list survey.
These data will be used to describe the usability of the
website, as well as caregivers’ choices of caregiving tasks
from suggested options.
Chart review
A registered nurse reviews the patient’s electronic medi-
cal record at week 14 or following withdrawal or death
to assess covariates (e.g. comorbidities, supportive care
received) and secondary outcomes (utilization, adher-
ence with chemotherapy, and adverse events). The nurse
reviews all inpatient and outpatient oncology notes writ-
ten from four weeks prior to 14 weeks after informed
consent. All modalities of cancer treatment and adjunct
supportive care received during the observation period
are noted (including consultations from palliative care
services or referrals to hospice or home health nursing).
Surgical procedures, the dose and duration of radiation
treatment, and the dose and duration of chemotherapy
(both recommended and actualized) will be noted, as
will any medication changes (and reasons thereof).
Description of Patient Measures
Summed symptom severity score
(source: patient baseline, 10 week, and 14 week surveys).
A summed symptom score will be generated based on
the sum of symptom severity scores (scored 0-10) across
the 8 core symptoms.
Adherence to chemotherapy
(source: medical record audit). Adherence to chemother-
a p yw i l lb ed e t e r m i n e db yt h et o t a ln u m b e ro fd o s e
reductions, infusion delays, and agent discontinuations.
Physical functioning
(source: patient baseline, 10 week, and 14 week surveys)
Physical functioning will be measured using the SF-36
summary measure for physical function which has an
alpha reliability exceeding 0.80 [36].
Utilization of services
(source: medical record audit). The utilization of inpati-
ent and outpatient services will be measured in terms of
the number of cancer-related: hospitalizations, visits to
emergency or urgent care, scheduled and unscheduled
contacts with oncology (in person or by phone), and
referrals to home health or hospice.
Self-efficacy
(source: patient baseline and 10 week surveys). The
Cancer Behavior Inventory
(CBI) Version 2 will be employed to measure patient
self-efficacy. The CBI has an internal validity of .94 and
covers 7 aspects of self-management, including: mainte-
nance of activity and independence, seeking and under-
standing medical information, stress management,
coping with side effects of treatment, accepting cancer/
maintaining positive attitude, affective regulation, and
seeking support [37].
Social support
(source: patient baseline and 10 week surveys). Two
dimensions of social support will be examined: actua-
lized and perceived. Actualized social support will be
measured using the Inventory of Socially Supportive
Behaviors (ISSB) [38]. The ISSB is a 40 item measure
that assesses the receipt of directive guidance (e.g. care-
giver suggested the patient take some action), nondirec-
tive support (e.g. caregiver expressed concern), positive
social exchange (e.g. the caregiver talked with patient
about non-cancer related interests), and tangible assis-
tance (e.g. caregiver drove patient to appointment). The
ISSB has excellent internal consistency and good test-
retest reliability (> 0.90) [38]. Perceived social support
will be measured using the Social Provisions Scale (SPS).
The internal consistency scores of the six subscales and
total scale of the SPS are above .70 and .90 respectively.
Description of Caregiver Measures
Caregiver burden
(source: caregiver baseline, 10 week, and 14 week sur-
veys). The Caregiver Reaction Assessment (CRA) mea-
sures 5 dimensions of caregiver burden, including:
caregiver esteem, lack of family support, impact on
finances, impact on schedule, and impact on health. The
CRA has good internal consistency (alpha 0.80-0.90)
and a high degree of reliability [39].
Caregiver distress (source: caregiver baseline, 10 week, and
14 week surveys)
We will employ the Center for Epidemiological Studies-
Depression Scale (CES-D) to measure depression in Car-
ePartners. The CES-D is a scale widely used to measure
depression in caregivers because of its ease of use (it has
20 items) and high reliability (alpha = 0.90) [40].
Mastery of caregiving
(source: caregiver baseline and 10 week surveys). Care-
giver mastery will be measured using the problem sol-
ving skill subscale of the caregiver self-efficacy
instrument by Zeiss; this subscale has a reliability of .83
[41].
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Research assistants rehearse an ATSA call with every
patient participant at the time of enrollment. They
review call data from ATSA regularly to identify patients
who do not respond to scheduled calls. When patients
do not respond to multiple ATSA attempts over 48
hours (at any period throughout the 10 weeks of the
trial), research assistants contact them to determine the
reason; reasons for non-compliance are tracked. Support
is offered to patients whose reason for noncompliance
relates to technical issues.
Similarly, for the first 4 weeks on the study, caregivers’
Web logs are reviewed to identify caregivers who either
have not been able to sign-in or create a task list.
Research assistants contact caregivers whose Web logs
indicate noncompliance and call caregivers to identify
the cause. Depending on the reason for the difficulty,
research assistants offer to guide the caregiver by tele-
phone during their next online session. Research assis-
tants track all reasons for noncompliance with the
website.
Patients and caregivers are not permitted to use ATSA
or the website until the baseline survey is completed. Data
is entered into a clinical data tracking system that alerts
staff of survey due dates and incomplete data. The date
the baseline survey is completed determines the dates for
the 10 and 14 week surveys. Up to 10 attempts are made
to contact each subject or caregiver for scheduling an
interview. Abbreviated versions of all interviews are avail-
able for patients who have difficulty completing the entire
survey. Patients and caregivers receive a $15 gift card for
each survey they complete. Monthly updates with com-
ments on completeness of data are maintained and
reviewed by the Project Manager.
The success of randomization is monitored quarterly by
comparing the demographic and clinical characteristics of
patients across study arms. Clinical staff is blinded to the
assignment arm, as are the analysts examining the data.
Monitoring and Reporting of Adverse Events
The study includes several mechanisms for monitoring
and identifying adverse events. First, symptom data from
ATSA are reviewed weekly by the Principal Investigator
(PI) who is a physician. When a patient reports multiple
symptoms at severe levels (7 or above), the PI reviews the
medical record to insure that the symptoms have been
recognized by oncology staff. In the event that there are
no progress notes indicating that the patient has been
recently seen or contacted, the PI calls the oncology nurse
case manager to alert them to the patient’sr e p o r t s .
When patients fail to respond to ATSA calls on two
consecutive days, research staff calls the patient to ensure
their safety. When patients cannot be reached, study staff
informs the caregiver and oncology nurse case manager.
Patients who are hospitalized are given the option to sus-
pend their ATSA calls. Patients enrolling in hospice are
given the option to come off study.
Subjects and clinicians have access to a toll-free number
they can call with study-related problems. Caregivers have
access to the research team’s contact information through
the website. Adverse clinical events are reported immedi-
ately to the clinician of record as well as the IRB. All
deaths are immediately investigated by a physician not
affiliated with the study in order to determine the cause.
Data Analysis
Sample Size Calculation
Testing the primary outcome using two sided t-testing
will require at least 224 dyads (patients and caregivers)
to complete the study (112 per arm). This sample size
affords 80% power to detect a difference as small as
0.33 standard deviations in mean summed symptom
severity (Hypothesis 1) and social support (Hypothesis
2) between arms using 0.05 as the level of significance.
This consistent with standards for clinical relevance
and those seen in similar interventions [26,42]. More-
over, this sample size is sufficient to accommodate
longitudinal analyses with repeated measures. To
account for 25% attrition (consistent with prior trials
of ATSA) and ensure that 112 dyads in each group are
available for analysis, the goal is to enroll 300 dyads in
the trial [26].
Preliminary Analysis
Graphical analyses will include: (1) examining distributions
of the various numerical outcome variables using box
plots and histograms to investigate skewness, gaps and
outliers; (2) side-by-side box plots and back-to-back histo-
grams to graphically rule out baseline differences in out-
comes between the two study groups; (3) plots of cross-
sectional outcome means over time to assess the longitu-
dinal trends within and between the two arms; and (4)
scatter plots of change in outcome variables versus change
in potential mediator variables. Variables with highly
skewed distributions will be transformed. When such
transformations are not successful, we will employ gener-
alized linear models in the primary analyses. In addition,
we will consider dichotomizing the variables using clini-
cally-relevant cut points.
Baseline Analysis
We will test for possible baseline differences in the out-
comes and characteristics of the patients and caregivers
in the two study groups including but not limited to:
patient and caregiver socio-demographic and clinical
characteristics, symptom scores, physical and mental
functioning, social support, caregiver relationship type
(spouse vs. other), and caregiver location (in-home vs.
out-of-home). If any significant baseline differences are
identified, intervention effects will be estimated using
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well as stratified analysis using propensity scores.
Attrition Analyses
To ensure the validity of findings, baseline characteristics
of patients and caregivers who drop out of the study will
be compared by study group. We will also summarize and
compare reasons for attrition. If any differences are found,
the appropriate covariance adjustments or propensity
score stratifications will be employed in the primary analy-
sis. To ensure the generalizability of our findings, we will
also compare the baseline characteristics of those complet-
ing the study against those of subjects who drop out.
Primary Analytic Strategy
The primary effect of the intervention will be determined
using data obtained at 10 weeks, and the sustained effect
will be determined using data obtained at 14 weeks. Cross
group comparisons will be made based on an intention-
to-treat basis. We will also test the hypotheses with a long-
itudinal design by fitting a linear mixed-effects modelor a
generalized linear mixed effects model to estimate effect
averaged over 10 and 14 weeks, adjusting for potential
within-person correlation and baseline values of the out-
come variables [15].
Missing Data
When missing values occur, we will determine whether
missingness is random or associated with patient or care-
giver characteristics using standard regression models. As
long as we do not observe any bias in patterns of dropout
or missing data (see attrition analysis above), we will use
regression techniques allowing for missing at random.
Models will include 10 and 14 week assessment data as
longitudinal outcome values, an intervention effect indica-
tor, and baseline values of the outcome variable and other
covariates as fixed independent variables. If the analyses
indicate that missingness depends on unobserved outcome
values(, we will account for missing data using a pattern
mixture model [43]. This technique allows the use of data
from all participants (not just completers) and provides an
unbiased intervention effect estimate.
Hypothesis Testing
We will compare summed symptom scores at 10 weeks
between the control and intervention groups using a mul-
tiple regression model. The model will include a dummy
variable for study group assignment as the main indepen-
dent variable and will be adjusted for baseline symptom
scores. While we do not expect the groups to be unba-
lanced with respect to other potential predictors of the
outcome, we will adjust for these if randomization is not
fully successful. The parameter estimate of the group
assignment dummy variable and its statistical significance
will estimate and test for the outcome difference between
the two study groups at week 10, adjusting for baseline
values of the outcome. A similar approach will be used to
test the intervention effect on secondary outcomes
(namely physical functioning, service utilization, and che-
motherapy adherence). To determine if there is mainte-
nance of the intervention effects on each outcome, we will
use a similar regression model using the corresponding
measurements at week 14, and a longitudinal model for
the outcomes at 10 and 14 weeks.
Our analytic approach for testing Hypothesis 2 will be
similar to that described above. We will use multiple
regression models to compare group differences in
patient-reported social support scores as measured by the
Inventory of Socially Supportive Behaviors at 10 weeks,
adjusting for baseline values of the ISSB [38]. The model
will include a dummy variable for study group assignment
as well as the baseline value of the ISSB scores, and the
parameter estimate of the dummy variable will estimate
the intervention effect on caregivers at 10 weeks. A similar
approach will be used to test the intervention effect on
caregiver burden and distress.
Mediation Analysis
To determine whether the improvements in patient out-
comes are mediated by patient self-efficacy and social sup-
port, we will employ the approach originally described by
Baron and Kenny and more recently further developed by
others [44-48]. In addition to the linear models relating
outcomes to study group, we will fit two additional models
relating mediator to the study group, and the model relat-
ing the outcome to the mediator and study group. To
establish mediation, the study group effect has to be signif-
icant in all but the last model. If in the last model the
study group effect is not significant, then we will conclude
that complete mediation has occurred. If in the last model
the study group effect is reduced, but is still significant,
then we will conclude that partial mediation has occurred.
To test for mediation, Sobel’s test will be carried out, and
percent of variation in outcomes mediated by patient or
caregiver mediators will be determined [49-51].
Discussion
Cancer patients undergoing chemotherapy experience
many symptoms which they can manage when given the
appropriate amount of information. However, self-man-
agement may not be sufficient or plausible for everyone.
To provide added support to patients for-whom self-man-
agement is challenging, we designed Cancer CarePartners-
a system offering automated telephonic monitoring of
patients with alerts and customized advice to a caregiver
via the Web. Our goal is to show that Cancer CarePartners
can enhance caregiver support for the patient, so that
patients engage in better self-management, and, in turn,
experience better symptoms, function, and adherence with
chemotherapy, ultimately requiring fewer formal resources
during and after treatment. If successful, this intervention
will be among the first to demonstrate that caregivers can
be formally engaged to improve clinical outcomes.
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also reduce caregiver burden and distress by enhancing
caregiver knowledge and mastery, it is possible that the
opposite may occur; thus, we will closely monitor care-
giver outcomes throughout the study. Should caregivers
experience increased burden from the intervention, the
reasons will need to be explored qualitatively in order to
inform the redesign of the system or revise caregiver
materials so that they are fully informed of the risks
prior to using Cancer CarePartners.
One potential limitation of the study is that not all
patients will have access to a caregiver with access to the
Web. Additionally, some patients, regardless of their
access to a caregiver, may not want to involve others in
their care or may prefer a ‘human touch’ over automa-
tion. We will closely monitor reasons for exclusion, refu-
sal and drop out to understand the prevalence of these
concerns so as to determine the generalizability of our
results. Still, we do not expect that Cancer CarePartners
will be appropriate for everyone. We posit that some
patients will continue to want or need the support of
clinicians by phone or face-to-face. Cancer CarePartners
is meant only to help clinicians more efficiently use their
time, not replace them.
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